What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Clinical trial evidence shows that guselkumab increases the likelihood of disease remission and endoscopic response compared with placebo. Although it has not been directly compared with risankizumab or vedolizumab, indirect comparisons suggest that it is likely to work as well as these alternatives, indicating a clear clinical advantage.
Does the economic case hold at the expected price? — Cost effectiveness
A cost comparison indicates that the costs for guselkumab are similar to or lower than those for risankizumab and vedolizumab, suggesting that it is clearly cost-effective under common thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data is not detailed in the document, the overall benefits of guselkumab in achieving disease remission and endoscopic response imply potential improvements in quality of life for patients with Crohn’s disease. However, the evidence is moderate and not explicitly quantified.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The document does not provide detailed safety data, but it implies that guselkumab is a viable option after other treatments have failed, suggesting an acceptable safety profile. However, specific adverse effects are not discussed, leading to some concerns.
Was the drug compared against what payers expect? — Comparator Selection
Guselkumab has not been directly compared in clinical trials with risankizumab or vedolizumab, which are key comparators. The reliance on indirect comparisons raises concerns about the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The population for which guselkumab is indicated is well-defined, targeting adults with previously treated moderately to severely active Crohn’s disease. The document suggests that it is intended for patients who have not responded to or cannot tolerate other treatments.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Guselkumab is positioned as a treatment option within existing care pathways for Crohn’s disease, requiring no significant changes to current practices. The guidance indicates that it should be funded and available within a specified timeframe, facilitating integration.
Are the wider system costs understood? — Resource Use and Cost Implications
The document indicates that guselkumab is to be funded within the NHS and suggests that its cost is manageable compared to alternatives. This implies a notable but justifiable cost burden with proportional benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence supporting guselkumab includes clinical trial data and indirect comparisons, which provide a reasonable level of robustness. However, the absence of direct head-to-head trials introduces some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the indirect comparisons, the overall context of unmet need for Crohn’s disease treatments and the supportive evidence for guselkumab’s efficacy mitigate these concerns.
